Namenda "not approvable" for mild-moderate Alzheimer’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest's Namenda (memantine) is "not approvable" for treatment of mild-to-moderate Alzheimer's disease, the firm says July 25. Two studies failing to show statistical significance led FDA to deny the indication. The sNDA included a third study showing statistical significance, but "FDA decided not to approve Namenda for mild patients based upon this single positive study in light of two previously disclosed, additional studies," Forest said. Namenda would have been the first AD agent approved for the full continuum of the disease. J&J's Risperdal (risperidone) also was deemed not approvable recently for an Alzheimer's-related indication (1Pharmaceutical Approvals Monthly June 2005, p. 13)...
You may also be interested in...
J&J Risperdal “Not Approvable” For Autism, Alzheimer’s Psychosis
Johnson & Johnson is considering how to proceed with Risperdalafter two supplemental applications for new indications for the atypical antipsychotic have been deemed "not approvable" by FDA
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.